Ronald K. Castellano

Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

RATIONALE It has been proposed that an activated renin angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary hypertension (PH). Recent studies have indicated that angiotensin-converting enzyme 2 (ACE2), a member of the vasoprotective axis of the RAS, plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Based on these observations, we propose the hypothesis that activation of endogenous ACE2 can shift the balance from the vasoconstrictive, proliferative axis (ACE-Ang II-AT1R) to the vasoprotective axis [ACE2-Ang-(1-7)-Mas] of the RAS, resulting in the prevention of PH. OBJECTIVES We have taken advantage of a recently discovered synthetic activator of ACE2, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), to study its effects on monocrotaline-induced PH in rats to support this hypothesis. METHODS The cardiopulmonary effects of XNT were evaluated in monocrotaline-induced PH rat model. MEASUREMENTS AND MAIN RESULTS A single subcutaneous treatment of monocrotaline in rats resulted in elevated right ventricular systolic pressure, right ventricular hypertrophy, increased pulmonary vessel wall thickness, and interstitial fibrosis. These changes were associated with increases in the mRNA levels of renin, ACE, angiotensinogen, AT1 receptors, and proinflammatory cytokines. All these features of PH were prevented in these monocrotaline-treated rats by chronic treatment with XNT. In addition, XNT caused an increase in the antiinflammatory cytokine, IL-10. CONCLUSIONS These observations provide conceptual support that activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling PH.

Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents

Angiotensin-converting enzyme 2 (ACE2) is a key renin-angiotensin system enzyme involved in balancing the adverse effects of angiotensin II on the cardiovascular system, and its overexpression by gene transfer is beneficial in cardiovascular disease. Therefore, our objectives were 2-fold: to identify compounds that enhance ACE2 activity using a novel conformation-based rational drug discovery strategy and to evaluate whether such compounds reverse hypertension-induced pathophysiologies. We used a unique virtual screening approach. In vitro assays revealed 2 compounds (a xanthenone and resorcinolnaphthalein) that enhanced ACE2 activity in a dose-dependent manner. Acute in vivo administration of the xanthenone resulted in a dose-dependent transient and robust decrease in blood pressure (at 10 mg/kg, spontaneously hypertensive rats decreased 71±9 mm Hg and Wistar-Kyoto rats decreased 21±8 mm Hg; P<0.05). Chronic infusion of the xanthenone (120 μg/day) resulted in a modest decrease in the spontaneously hypertensive rat blood pressure (17 mm Hg; 2-way ANOVA; P<0.05), whereas it had no effect in Wistar-Kyoto rats. Strikingly, the decrease in blood pressure was also associated with improvements in cardiac function and reversal of myocardial, perivascular, and renal fibrosis in the spontaneously hypertensive rats. We conclude that structure-based screening can help identify compounds that activate ACE2, decrease blood pressure, and reverse tissue remodeling. Administration of ACE2 activators may be a valid strategy for antihypertensive therapy.

ACE2 activation promotes antithrombotic activity.

The aim of the present study was to test the hypothesis that the activation of the angiotensin-converting enzyme (ACE)2/angiotensin-(1–7)/Mas receptor axis by use of a novel ACE2 activator (XNT) would protect against thrombosis. Thrombi were induced in the vena cava of spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) rats, and ACE2 and ACE activity in the thrombus was determined. Real-time thrombus formation was viewed through intravital microscopy of vessels in nude mice. Thrombus weight was 40% greater in the SHR (4.99 ± 0.39 versus 7.04 ± 0.66 mg). This weight increase was associated with a 20% decrease in ACE2 activity in the thrombus. In contrast, there were no differences between the WKY and SHR in ACE2 protein and ACE activity in the thrombi. ACE2 inhibition (DX600; 0.1 µmol/L/kg) increased thrombus weight by 30% and XNT treatment (10 mg/kg) resulted in a 30% attenuation of thrombus formation in the SHR. Moreover, XNT reduced platelet attachment to injured vessels, reduced thrombus size, and prolonged the time for complete vessel occlusion in mice. Thus, a decrease in thrombus ACE2 activity is associated with increased thrombus formation in SHR. Furthermore, ACE2 activation attenuates thrombus formation and reduces platelet attachment to vessels. These results suggest that ACE2 could be a novel target for the treatment of thrombogenic diseases.

De novo design, synthesis, and in vitro evaluation of inhibitors for prokaryotic tRNA-guanine transglycosylase: A dramatic sulfur effect on binding affinity

Shigellosis (bacillary dysentary) is a bacterial disease that results in more than one million deaths each year. Enteric infections caused by the Shigella organisms have traditionally been treated with antibiotics. However, the emergence of multi-drugresistant strains and a longstanding lack of vaccine availability demands the development of novel therapeutic strategies. To this end, tRNA-guanine transglycosylase (TGT, EC2.4.2.29) has been recognized as a key enzyme in the regulation of bacterial virulence and a target for de novo drug design, as shown by Gr‰dler et al. TGT is involved in the biosynthesis of the highly modified nucleobase queuine (Q; Scheme 1) found in the anticodon loop of some tRNAs. Prokaryotic TGT catalyzes the exchange of guanine from the anticodon loop with the queuine precursor

Consequences of hydrogen bonding on molecular organization and charge transport in molecular organic photovoltaic materials

Reported is a systematic molecular structure–property relationship study to evaluate the consequences of dedicated H-bonding interactions between molecular electron donors on molecular assembly, absorption, charge collection, and performance in small-molecule bulk heterojunction organic photovoltaic devices. Three families of branched quaterthiophene donor chromophores have been synthesized with members that share nearly identical electronic and optical properties in the molecularly dispersed state but are either capable or incapable of self-association by hydrogen bonding (H-bonding). Phthalhydrazide-functionalized quaterthiophenes are H-bond “active” and show signatures of H-bond promoted assembly in solution (by 1H NMR) and in both neat and blended (with C60) films (by IR). Compared to control compounds with H-bonding “turned off”, the H-bonded derivatives show red-shifted thin film absorption (neat and as blends with C60), different colors as bulk solids, and increased decomposition and melt temperatures. Photovoltaic devices made from blends of H-bonded donor molecules with C60 as the electron acceptor show improved charge collection length and external quantum efficiency resulting in a more than two-fold enhancement in power conversion efficiency relative to non-H-bonding controls, from 0.49% to 1.04%. We anticipate this approach could be generalized to include other donor chromophores with lower optical gap to harvest more longer-wavelength photons and achieve higher power conversion efficiencies.

Highly fluorescent donor–acceptor purines

Donor–acceptor purines have been prepared that show near unity fluorescence quantum yields in organic solution, a step toward using simple biorelevant heterocycles in optoelectronic and photonic applications.

Ultraviolet-violet electroluminescence from highly fluorescent purines

We report efficient ultraviolet (UV)-violet organic light-emitting devices (OLEDs) based on highly fluorescent donor–acceptor purine molecules, which can generate tunable emission from 350 nm to 450 nm in solution by using different electron donor and acceptor arrangements on the heterocycles as reported previously. Here, external quantum efficiencies (EQEs) up to ηEQE = 1.6% are achieved for the multilayer OLEDs based on purine 2, with UV emission peaked at 393 nm, as compared to previously reported purine 1 based OLEDs with ηEQE = 3.1% and peak emission at 433 nm. The efficiencies of the OLEDs based on the two purine molecules are among the highest reported to date with emission peak wavelengths below 450 nm. By using a range of charge transport and host materials, we show that appropriate energy level alignment in multilayer OLED devices is imperative to achieve UV emission and prevent undesired emission from other layers or interfaces.

Benzotrifuranone: synthesis, structure, and access to polycyclic heteroaromatics.

Functionalized benzotrifurans can be accessed in one efficient acylation step from previously unreported benzotrifuranone. DFT calculations have confirmed the aromaticity of the heteroaromatic system and determined its electronic structure that is relevant to applications in materials and supramolecular chemistry.

H-Bonded complexes of adenine with Rebek imide receptors are stabilised by cation–π interactions and destabilised by stacking with perfluoroaromatics

A series of Rebek imide receptors with naphthalene or heteroaromatic platforms attached by amide or ester linkers have been prepared from the corresponding acyl chloride or anhydride; the X-ray crystal structure of the receptor-derived anhydride reveals a supramolecular H-bonded helix formation in the crystal; the complexes of adenine bound to the receptors by Hoogsteen H-bonding are found to be stabilised by stacking with a methylquinolinium ion, but destabilised by stacking with a perfluorinated naphthalene.

ACE2/Ang-(1–7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells

CD34(+) stem/progenitor cells have been identified as a promising cell population for the autologous cell-based therapies in patients with cardiovascular disease. The counter-regulatory axes of renin angiotensin system, angiotensin converting enzyme (ACE)/Ang II/angiotensin type 1 (AT1) receptor and ACE2/Ang-(1-7)/Mas receptor, play an important role in the cardiovascular repair. This study evaluated the expression and vascular repair-relevant functions of these two pathways in human CD34(+) cells. CD34(+) cells were isolated from peripheral blood mononuclear cells (MNCs), obtained from healthy volunteers. Expression of ACE, ACE2, AT1, and angiotensin type 2 and Mas receptors were determined. Effects of Ang II, Ang-(1-7), Norleu(3)-Ang-(1-7), and ACE2 activators, xanthenone (XNT) and diminazene aceturate (DIZE) on proliferation, migration, and adhesion of CD34(+) cells were evaluated. ACE2 and Mas were relatively highly expressed in CD34(+) cells compared with MNCs. Ang-(1-7) or its analog, Norleu(3)-Ang-(1-7), stimulated proliferation of CD34(+) cells that was associated with decrease in phosphatase and tensin homologue deleted on chromosome 10 levels and was inhibited by triciribin, an AKT inhibitor. Migration of CD34(+) cells was enhanced by Ang-(1-7) or Norleu(3)-Ang-(1-7) that was decreased by a Rho-kinase inhibitor, Y-27632. In the presence of Ang II, XNT or DIZE enhanced proliferation and migration that were blocked by DX-600, an ACE2 inhibitor. Treatment of MNCs with Ang II, before the isolation of CD34(+) cells, attenuated the proliferation and migration to stromal derived factor-1α. This attenuation was reversed by apocynin, an NADPH oxidase inhibitor. Adhesion of MNCs or CD34(+) cells to fibronectin was enhanced by Ang II and was unaffected by Ang-(1-7). This study suggests that ACE2/Ang-(1-7)/Mas pathway stimulates functions of CD34(+) cells that are cardiovascular protective, whereas Ang II attenuates these functions by acting on MNCs. These findings imply that activation of ACE2/Ang-(1-7)/Mas axis is a promising approach for enhancing reparative outcomes of cell-based therapies.